MW

Michael Winlo

Emyria Limited | Managing Director
Dr Winlo has a leadership experience across the biotechnology, pharmaceutical and technology sectors. He is currently Chief Executive Officer. Dr Winlo also serves as a director and former CEO of Linear Clinical Research, a world-class provider of early and late-stage pharmaceutical trial facilities and management services. Prior to his role at Linear, Dr Winlo was based in Silicon Valley for five years as the Health Lead at Palantir Technologies (NYSE: PLTR).

Companies and Roles

Company
Title
Tenure
Since
EMD
EMD
Emyria Limited
  • Managing Director
5yrs, 2mthNov 2019
DVL
DVL
Dorsavi Ltd
  • Non-Executive Director
1yrs, 2mthOct 2023
NVU
NVU
Nanoveu Limited
  • Non-Executive Director
1yrs, 9mthMar 2023

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
DVL
DVL
Dorsavi Ltd
15/11/243,251,940N/A454,545N/A
EMD
EMD
Emyria Limited
20/09/241,046,519N/A7,343,259N/A
NVU
NVU
Nanoveu Limited
03/04/24346,154N/A173,077N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
NVU
NVU
Nanoveu Limited
06/01/25
Issued
2,040,000$0.036$73,440Issue of securities
DVL
DVL
Dorsavi Ltd
15/11/24
Issued
454,545$0.012$5,454Placement
DVL
DVL
Dorsavi Ltd
15/11/24
Issued
454,545$0.011$4,999Placement
DVL
DVL
Dorsavi Ltd
15/11/24
Issued
2,797,394$0.012$32,729Placement
EMD
EMD
Emyria Limited
20/09/24
Issued
200,000$0.037$7,400Placement